Multiobjective optimization of fluphenazine nanocomposite formulation using NSGA-II method

• Autorzy: Abu Sharar Ahmed Adnan , Ramadan Saleem Z. , Hussein-Al-Ali Samer Hasan

Identyfikatory

DOI

10.2478/msp-2021-0042

• Języki publikacji: EN

Abstrakty

EN

The World Health Organization (WHO, 2019) reports that schizophrenia affects approximately 20 million people worldwide, and the annual number of new cases is estimated at 1.5%/10,000 people. As a result, there is a demand for making the relevant medicines work better. Using a fluphenazine (FZN) drug delivery system that has been optimized using nanoparticles (NPs) technology is an important alternative treatment option for noncompliant patients with schizophrenia. Compared to the conventional delivery system, the NPs delivery system provides a controlled-release treatment, minimizes drug levels reaching the blood, and has fewer side effects as well. As a result of using the NPs delivery system, patients can obtain the benefits of reduced daily dosing and improved compliance. In this context, this study was performed to develop a mathematical model for FZN to optimize its nanocomposite delivery system using a mixture-process DoE and multiobjective optimization (MOO) approaches. The influences of NPs input fabrication parameters [i.e., FZN percentage, chitosan (CS) percentage, sodium tripolyphosphate (TPP) percentage, and pH] were investigated by mixture-designed experiments and analyzed by analysis of variance (ANOVA); subsequently, based on the results of the analysis, three regression models were built for size, zeta potential (ZP), and drug loading efficiency (LE%); and thereafter, these models were validated using 26 experiments with three replicates. The MOO approach was employed using a non-dominated sorting genetic algorithm (NSGA-II) to provide the optimal fitness value of each objective function by minimizing NPs size, maximizing ZP, and maximizing LE%. Test of hypotheses showed no statistical differences between the average observed values and the corresponding predicted values calculated by the regression models (126.6 nm, 18.7 mV, and 91.6%, respectively). As there is no benchmark available for the optimal NPs input fabrication parameters in the literature, the optimized formulation was further characterized using X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), polydispersity index (PdI), and differential scanning calorimetry (DSC). Those tests indicated that FZN was successfully encapsulated into the final nanocomposite. Furthermore, an in-vitro drug release study was carried out and showed that at least 5 days would be needed for FZN to be fully released from its nanocomposite in a sustained-release pattern. The nanocomposite could serve as a model for the controlled and extended delivery of many drugs.

Słowa kluczowe

EN

mixture design of experiment; multiobjective optimization; NSGA-II; nanoparticles; fluphenazine drug; regression analysis

• Wydawca: De Gruyter
• Czasopismo: Materials Science Poland
• Rocznik: 2021
• Tom: Vol. 39, No. 4
• Strony: 517--544
• Opis fizyczny: Bibliogr. 66 poz., rys., tab.

Twórcy

autor

Abu Sharar Ahmed Adnan

• Department of Industrial Engineering, School of Applied Technical Sciences, German Jordanian University-Jordan, Amman– Jordan

autor

Ramadan Saleem Z.

• Department of Industrial Engineering, School of Applied Technical Sciences, German Jordanian University-Jordan, Amman– Jordan

autor

Hussein-Al-Ali Samer Hasan

• Basic Pharmaceutical Sciences, Faculty of Pharmacy, Isra University-Jordan, Amman – Jordan

Bibliografia

• [1] Goyal S, Agarwal G, Agarwal S, Karar PK. Oral sustained release tablets: an overview with a special emphasis on matrix tablet. Am J Adv Drug Deliv. 2017;5(2) 064–076: http://doi.org/10.21767/2321-547X.1000013.
• [2] Pragati S, Ashok S. Recent advances in periodontal drug delivery systems. Int J Drug Deliv. 2009;1(1):1–14. http://doi.org/10.5138/ijdd.2009.0975.0215.01001.
• [3] Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019;4(1):33. http://doi.org/10.1038/s41392-019-0068-3.
• [4] McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76. http://doi.org/10.1093/epirev/mxn001.
• [5] WHO. Schizophrenia. 2019. 2019. https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia. Accessed 3 Apr 2021.
• [6] SARDAA. About Schizophrenia | SARDAA. Schizophrenia and related disorders alliance of America. 2020. https://sczaction.org/. Accessed 2 Apr 2021.
• [7] American Addiction Centers. Schizophrenia symptoms, patterns and statistics and patterns. MentalHelp. net. 2020. https://www.mentalhelp.net/schizophrenia/statistics/. Accessed 16 Apr 2021.
• [8] Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont). 2005;2(3):36–41. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3004713. Accessed 2 Apr 2021
• [9] James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7.
• [10] Quarantelli M, Palladino O, Prinster A, Schiavone V, Carotenuto B, Brunetti A, et al. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. Biomed Res Int. 2014;2014(1):1–9. https://doi.org/10.1155/2014/325052.
• [11] Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and metaanalysis. Syst Rev. 2020;9(1):17. https://doi.org/doi.org/10.1186/s13643-020-1274-3.
• [12] Staring ABP, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010; 197(6):448–455. https://doi.org/10.1192/bjp.bp.110.077289.
• [13] Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–769. https://doi.org/10.18553/jmcp.2015.21.9.754.
• [14] MPR. Fluphenazine dosage & Rx info | uses, side effects. MPR (The Right Dose of Information). 2021. https://www.empr.com/drug/fluphenazine/. Accessed 23 May 2021.
• [15] Rxlist. Prolixin (Fluphenazine): uses, dosage, side effects, interactions, warning. RxList. 2017. https://www.rxlist.com/prolixin-drug.htm. Accessed 12 Apr 2021.
• [16] Wirshing DA, Buckley PF. Schizophrenia treatment challenges. Psychiatric Times. 2003. https://www.psychiatrictimes.com/view/schizophrenia-treatment-challenges. Accessed 12 Apr 2021.
• [17] Singh B, Bhatowa R, Tripathi C, Kapil R. Developing micro-/nanoparticulate drug delivery systems using ‘design of experiments’. Int J Pharm Investig. 2011;1(2):75. https://doi.org/10.4103/2230-973X.82395.
• [18] Asmawi AA, Salim N, Abdulmalek E, Abdul Rahman MB. Modeling the effect of composition on formation of aerosolized nanoemulsion system encapsulating docetaxel and curcumin using D-optimal mixture experimental design. Int J Mol Sci. 2020;21(12):4357. https://doi.org/10.3390/ijms21124357.
• [19] Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model. Int J Pharm. 2018;541(1–2):198–205. https://doi.org/10.1016/j.ijpharm.2018.02.010.
• [20] Teja SPS, Damodharan N. 2 3 full factorial model for particle size optimization of methotrexate loaded chitosan nanocarriers: A design of experiments (DoE) approach. Biomed Res Int. 2018;1:1–9. https://doi.org/10.1155/2018/7834159.
• [21] Mandlik SK, Ranpise NS. Implementation of experimental design methodology in preparation and characterization of zolmitriptan loaded chitosan nanoparticles. Int Curr Pharm J. 2017; 6(3):16–22. https://doi.org/10.3329/icpj.v6i3.32684.
• [22] Politis DMN, Colombo S, Colombo P, Rekkas G. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889–901. https://doi.org/10.1080/03639045.2017.1291672.
• [23] Anderson-Cook CM, Goldfarb HB, Borror CM, Montgomery DC, Canter KG, Twist JN. Mixture and mixtureprocess variable experiments for pharmaceutical applications. Pharm Stat. 2004;3(4):247–260. https://doi.org/10.1002/pst.138.
• [24] Brits R, Engelbrecht AP, van den Bergh F. Locating multiple optima using particle swarm optimization. Appl Math Comput. 2007;189(2):1859–1883. https://doi.org/10.1016/j.amc.2006.12.066.
• [25] Ansary MAT, Panda G. A sequential quadratic programming method for constrained multi-objective optimization problems. J Appl Math Comput. 2020;64(1–2):379–397. https://doi.org/10.1007/s12190-020-01359-y.
• [26] Nicolaou CA, Brown N. Multi-objective optimization methods in drug design. Drug Discov Today Technol. 2013;10(3):427–435. https://doi.org/10.1016/j.ddtec.2013.02.001.
• [27] Perez-Escobedo JL, Azzaro-Pantel C, Pibouleau L. Multiobjective strategies for new product development in the pharmaceutical industry. Comput Chem Eng. 2012;37(1):278–296. https://doi.org/10.1016/j.compchemeng.2011.10.004.
• [28] Furtuna R, Curteanu S, Racles C. NSGA-II-RJG applied to multi-objective optimization of polymeric nanoparticles synthesis with silicone surfactants. Open Chem. 2011;9(6):1080–1095. https://doi.org/10.2478/s11532-011-0096-5.
• [29] Deb K, Pratap A, Agarwal S, Meyarivan T. A fast and elitist multiobjective genetic algorithm: NSGA-II. IEEE Trans Evol Comput. 2002;6(2):182–197. https://doi.org/10.1109/4235.996017.
• [30] Hemmat Esfe M, Razi P, Hajmohammad MH, Rostamian SH, Sarsam WH, Abbasian Arani AA, et al., Optimization, modeling and accurate prediction of thermal conductivity and dynamic viscosity of stabilized ethylene glycol and water mixture Al 2 O 3 nanofluids by NSGA-II using ANN. Int Commun Heat Mass Transf. 2017;82(1):154–160. https://doi.org/10.1016/j.icheatmasstransfer.2016.08.015.
• [31] Hemmat Esfe M, Motallebi SM. Four objective optimization of aluminum nanoparticles/oil, focusing on thermo-physical properties optimization. Powder Technol. 2019;356(1):832–846. https://doi.org/10.1016/j.powtec.2019.08.041.
• [32] Moslemi S, Zavvar Sabegh MH, Mirzazadeh A, Ozturkoglu Y, Maass E. A multi-objective model for multi-production and multi-echelon closed-loop pharmaceutical supply chain considering quality concepts: NSGAII approach. Int J Syst Assur Eng Manag. 2017;8(S2):1717–1733. https://doi.org/10.1007/s13198-017-0650-4.
• [33] Baghaei B, Saeb MR, Jafari SH, Khonakdar HA, Rezaee B, Goodarzi V, et al. Modeling and closed-loop control of particle size and initial burst of PLGA biodegradable nanoparticles for targeted drug delivery. J Appl Polym Sci. 2017;134(33):45145. https://doi.org/10.1002/app.45145.
• [34] Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125–132. https://doi.org/10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4.
• [35] Pedroso-Santana S, Fleitas-Salazar N. Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes. Polym Int. 2020;69(5):443–447. https://doi.org/10.1002/pi.5970.
• [36] Lazaridou M, Christodoulou E, Nerantzaki M, Kostoglou M, Lambropoulou DA, Katsarou A, et al. Formulation and in-vitro characterization of chitosan-nanoparticles loaded with the iron chelator deferoxamine mesylate (DFO). Pharmaceutics. 2020;12(3):238. https://doi.org/10.3390/pharmaceutics12030238.
• [37] Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10(1):483–507. https://doi.org/10.2147/DDDT.S99651.
• [38] Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems – a review (part 2). Trop J Pharm Res. 2013;12(2):265–273. https://doi.org/10.4314/tjpr.v12i2.20.
• [39] Aktar Demirtas E, Ayva O, Buruk Y. A case study in mixture design: multi response optimization of glaze formulation. Qual Eng. 2015;27(2):186–195. https://doi.org/10.1080/08982112.2014.942038.
• [40] Gozalvez JM, Garcia-Diaz JC. Mixture design experiments applied to the formulation of colorant solutions. J Chem Educ. 2006;83(4):647. https://doi.org/10.1021/ed083p647.
• [41] MinitabR 18 Support. Comparing full factorial and fractional designs in mixtures designs. 2019. https://support.minitab.com/en-us/minitab/18/help-and-how-to/modeling-statistics/doe/supporting-topics/mixture-designs/comparing-full-factorial-and-fractional-designs. Accessed 5 Feb. 2021.
• [42] Hinkelmann K. Design and analysis of experiments. vol. 3. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012.
• [43] Solomon J. Constrained optimization. In: Numerical algorithms: methods for computer vision, machine learning, and graphics. 1st ed., vol. 20, no. 5. A K Peters/CRC Press New Yourk; 2015. pp. 206–227.
• [44] Vachhani VL, Dabhi VK, Prajapati HB. Survey of multi objective evolutionary algorithms. In: 2015 international conference on circuits, power and computing technologies [ICCPCT-2015], Mar. 2015, pp. 1–9. https://doi.org/10.1109/ICCPCT.2015.7159422.
• [45] Vachhani VL, Dabhi VK, Prajapati HB. Improving NSGA-II for solving multi objective function optimization problems. In: 2016 International conference on computer communication and informatics (ICCCI); 2016. pp. 1–6, https://doi.org/10.1109/ICCCI.2016.7479921.
• [46] Acampora G, Kaymak U, Loia V, Vitiello A. Applying NSGA-II for solving the ontology alignment problem. In: 2013 IEEE international conference on systems, man, and cybernetics; Oct. 2013, pp. 1098–1103. https://doi.org/10.1109/SMC.2013.191.
• [47] Clayton KN, Salameh JW, Wereley ST, Kinzer-Ursem TL. Physical characterization of nanoparticle size and surface modification using particle scattering diffusometry. Biomicrofluidics. 2016;10(5):1–14. https://doi.org/10.1063/1.4962992.
• [48] Scrivens G, Ticehurst M, Swanson JT. Strategies for improving the reliability of accelerated predictive stability (APS) studies. In: Fenghe Qiu GS, editor. Accelerated predictive stability, Elsevier; Amsterdam, 2018, pp. 175–206.
• [49] Devaraj P, Kumari P, Aarti C, Renganathan A. Synthesis and characterization of silver nanoparticles using cannonball leaves and their cytotoxic activity against MCF- 7 cell line. J Nanotechnol. 2013;2013(1):1–5. https://doi.org/10.1155/2013/598328.
• [50] Kanha P, Saengkwamsawang P. Effect of stirring time on morphology and crystalline features of MnO 2 nanoparticles synthesized by co-precipitation method. Inorg Nano-Metal Chem. 2017;47(8):1129–1133. https://doi.org/10.1080/24701556.2017.1284100.
• [51] Topp R, Gomez G. Residual analysis in linear regression models with an interval-censored covariate. Stat Med. 2004;23(21):3377–3391. https://doi.org/10.1002/sim.1731.
• [52] Casson RJ, Farmer LDM. Understanding and checking the assumptions of linear regression: a primer for medical researchers. Clin Experiment Ophthalmol. 2014;42(6):590–596. https://doi.org/10.1111/ceo.12358.
• [53] Martin J, de Adana DDR, Asuero AG. Fitting models to data: residual analysis, a primer. In: Uncertainty quantification and model calibration. Jan Peter Hessling, In-Tech. London, 2017, pp. 791–796.
• [54] Zhao X, Zhang Y, Xie S, Qin Q, Wu S, Luo B. Outlier detection based on residual histogram preference for geometric multi-model fitting. Sensors. 2020;20(11):3037. https://doi.org/10.3390/s20113037.
• [55] Zielińska A, Carreiro F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. https://doi.org/10.3390/molecules25163731.
• [56] Khaira R, Sharma J, Saini V. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride. ScientificWorldJournal. 2014;2014(1):6. https://doi.org/10.1155/2014/560962.
• [57] Chaturvedi S, Rajasekar E, Natarajan S, Multiobjective building design optimization under operational uncertainties using the NSGA II algorithm. Buildings. 2020;10(5):88. https://doi.org/10.3390/buildings10050088.
• [58] Yuan Z, Ye Y, Gao F, Yuan H, Lan M, Lou K, et al. Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. Int J Pharm. 2013;446(1–2):191–198. https://doi.org/10.1016/j.ijpharm.2013.02.024.
• [59] Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015;125(1):75–84. https://doi.org/10.1016/j.ces.2014.08.046.
• [60] Kalaivani R, Maruthupandy M, Muneeswaran T, Hameedha Beevi A, Anand M, Ramakritinan CM, et al. Synthesis of chitosan mediated silver nanoparticles (Ag NPs) for potential antimicrobial applications. Front Lab Med. 2018;2(1):30–35. https://doi.org/10.1016/j.flm.2018.04.002.
• [61] Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MMA. Characterization and anti-proliferative activity of curcumin loaded chitosan nanoparticles in cervical cancer. Int J Biol Macromol. 2016;93(1):242–253. https://doi.org/10.1016/j.ijbiomac.2016.08.050.
• [62] Hu D, Lin C, Liu L, Li S, Zhao Y. Preparation, characterization, and in vitro release investigation of lutein/zein nanoparticles via solution enhanced dispersion by supercritical fluids. J Food Eng. 2012;109(3):545–552. https://doi.org/10.1016/j.jfoodeng.2011.10.025.
• [63] Ciesĺik-Boczula K, Szwed J, Jaszczyszyn A, Gasiorowski K, Koll A. Interactions of dihydrochloride fluphenazine with DPPC liposomes: ATR-IR and 31 P NMR studies. J Phys Chem B. 2009;113(47):15495–15502. https://doi.org/10.1021/jp904805t.
• [64] Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res. 2004;339(16):2693–2700. https://doi.org/10.1016/j.carres.2004.09.007.
• [65] Tang ESK, Huang M, Lim LY. Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm. 2003;265(1–2):103–114. https://doi.org/10.1016/S0378-5173(03)00408-3.
• [66] Knaul JZ, Hudson SM, Creber KAM. Improved mechanical properties of chitosan fibers. J Appl Polym Sci. 1999;72(13):1721–1732. https://doi.org/10.1002/(SICI)1097-4628(19990624)72:13<1721::AID-APP8>3.0.CO;2-V.